mpMRI联合          <sup>99m</sup>Tc-PSMA SPECT/CT检测前列腺癌新辅助雄激素剥夺治疗后显著残留病灶的价值研究

周冰妮; 刘晓航; 顾丙新; 周良平; 顾雅佳

doi:10.19401/j.cnki.1007-3639.2022.02.005

您当前的位置：

首页 >

文章列表页 >

mpMRI联合 ^99mTc-PSMA SPECT/CT检测前列腺癌新辅助雄激素剥夺治疗后显著残留病灶的价值研究

论著 | 更新时间：2025-12-31

- mpMRI联合 ^99mTc-PSMA SPECT/CT检测前列腺癌新辅助雄激素剥夺治疗后显著残留病灶的价值研究
- The value of mpMRI combined with ^99mTc-PSMA SPECT/CT in the detection of significant residual prostate cancer after neoadjuvant androgen deprivation therapy
- 中国癌症杂志 2022年32卷第2期页码：134-141
- 作者机构：
  
  1. 复旦大学附属肿瘤医院放射诊断科,复旦大学上海医学院肿瘤学系,上海 200032
  2. 复旦大学附属肿瘤医院核医学科,复旦大学上海医学院肿瘤学系,上海 200032
- 作者简介：
  
  GU Yajia E-mail: cjr.guyajia@vip.163.com
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2022.02.005
  中图分类号： R737.25
- 收稿：2021-11-03，
  
  纸质出版：2022-02-28
- 稿件说明：
移动端阅览
周冰妮, 刘晓航, 顾丙新, 等. mpMRI联合 ^99mTc-PSMA SPECT/CT检测前列腺癌新辅助雄激素剥夺治疗后显著残留病灶的价值研究[J]. 中国癌症杂志, 2022,32(2):134-141.

Bingni ZHOU, Xiaohang LIU, Bingxin GU, et al. The value of mpMRI combined with ^99mTc-PSMA SPECT/CT in the detection of significant residual prostate cancer after neoadjuvant androgen deprivation therapy[J]. China Oncology, 2022, 32(2): 134-141.
周冰妮, 刘晓航, 顾丙新, 等. mpMRI联合 ^99mTc-PSMA SPECT/CT检测前列腺癌新辅助雄激素剥夺治疗后显著残留病灶的价值研究[J]. 中国癌症杂志, 2022,32(2):134-141. DOI： 10.19401/j.cnki.1007-3639.2022.02.005.

Bingni ZHOU, Xiaohang LIU, Bingxin GU, et al. The value of mpMRI combined with ^99mTc-PSMA SPECT/CT in the detection of significant residual prostate cancer after neoadjuvant androgen deprivation therapy[J]. China Oncology, 2022, 32(2): 134-141. DOI： 10.19401/j.cnki.1007-3639.2022.02.005.

摘要

背景与目的：

雄激素剥夺治疗（androgen deprivation therapy

ADT）是前列腺癌患者常用的治疗方法之一

然而对于ADT后病灶的变化

目前仍缺乏直接、精准的评估方法。以术后病理学检查结果作为金标准

初步探讨多参数磁共振成像（multiparametric magnetic resonance imaging

mpMRI）联合

99m

Tc标记前列腺特异性膜抗原（prostate specific membrane antigen

PSMA）小分子抑制剂（HYNIC-Glu-Urea-A

简称

99m

Tc-PSMA）单光子发射计算机体层成像（single photon emission computed tomography

SPECT）/计算机体层成像（computed tomography

CT）评估前列腺癌新辅助ADT后的疗效

即检测显著残留病灶的价值。

方法

回顾并分析2017年3月—2021年7月复旦大学附属肿瘤医院收治的154例接受新辅助ADT后行根治性前列腺切除术的前列腺癌患者的临床资料。所有患者均在术前行mpMRI及

99m

Tc-PSMA SPECT/CT检查

根据术后病理学检查结果分为显著残留组及完全缓解/微残留两组。比较两组的临床病理学特征、mpMRI前列腺局部复发磁共振成像报告评分（Prostate Magnetic Resonance Imaging for Local Recurrence Reporting

PI-RR）分数及

99m

Tc-PSMA SPECT/CT阳性率。采用受试者工作特征（receiver operating characteristic

ROC）曲线及曲线下面积（area under curve

AUC）分析mpMRI、

99m

Tc-PSMA SPECT/CT单独使用及联合使用时的诊断效能差异。

结果

术后病理学检查结果证实显著残留组128例、完全缓解/微残留组26例。患者平均年龄为（66.88±7.79）岁

中位年龄68岁

年龄47~85岁。两组患者年龄、初始PSA、Gleason评分差异无统计学意义（

0.05）;而新辅助ADT后PSA显著残留组明显高于完全缓解/微残留组

差异有统计学意义（

0.05）。mpMRI诊断显著残留的AUC值为0.713

以PI-RR评分3为界值时灵敏度为78.13%

特异度为30.77%;以PI-RR评分4为界值时灵敏度为68.75%

特异度为69.23%。

99m

Tc-PSMA SPECT/CT诊断显著残留的AUC值为0.729

与mpMRI相比差异无统计学意义（

0.05）

灵敏度为76.56%

特异度为69.23%。mpMRI联合

99m

Tc-PSMA SPECT/CT使用时AUC为0.809

显著高于两者单独使用时（

0.05）。

结论

mpMRI与

99m

Tc-PSMA SPECT/CT均可用于诊断前列腺癌新辅助ADT后显著残留灶

两者联合运用时可以显著提高诊断效能。

Abstract

Background and purpose:

Androgen deprivation therapy (ADT) is a key primary treatment for prostate cancer. However

there is still a lack of direct and accurate assessment method for the changes in the lesions after ADT treatment. The aim of this study was to explore the value of multiparametric magnetic resonance imaging (mpMRI) combined with technetium-99m labelled small molecule against prostate specific membrane antigen (PSMA) (HYNIC-Glu-Urea-A

99m

Tc-PSMA) single photon emission computed tomography (SPECT)/computed tomography (CT) in the detection of significant residual prostate cancer after neoadjuvant ADT with the reference standard of postoperative pathology.

Methods:

A retrospective analysis of 154 prostate cancer patients treated in Fudan University Shanghai Cancer Center from March 2017 to July 2021 who underwent radical prostatectomy (RP) after neoadjuvant ADT was performed. All patients underwent preoperative mpMRI and

99m

Tc-PSMA SPECT/CT. Patients were divided into two groups according to the postoperative pathology: the significant residual group and complete response or minimum residual disease (CR/MRD) group. The clinical characteristics

the scores of Prostate Magnetic Resonance Imaging for Local Recurrence Reporting (PI-RR) system and the positive rate of

99m

Tc-PSMA SPECT/CT of the two groups were compared. The differences among the diagno

stic efficacy of mpMRI and

99m

Tc-PSMA SPECT/CT alone and in combination were analyzed by the receiver operating characteristic (ROC) curve and the area under curve (AUC).

Results:

In total

the significant residual group consisted of 128 patients

and the CR/MRD group consisted of 26 patients. The average and median age of the patients were 66.88±7.79 (ranged from 47 to 85) years and 68 years

respectively. There was no statistical difference in age

PSA before neoadjuvant ADT and Gleason scores between the two groups

while PSA after neoadjuvant ADT of the significant residual group was significantly higher than that of the CR/MRD group. The AUC of mpMRI was 0.713

the sensitivity and specificity were 78.13% and 30.77%

respectively

with a cut-off of PI-RR score 3

while sensitivity and specificity were 68.75% and 69.23%

respectively

with a cut-off of PI-RR score 4. The AUC of

99m

Tc-PSMA SPECT/CT was 0.729

the sensitivity and specificity were 76.56% and 69.23%

respectively. The AUC of mpMRI combined with

99m

Tc-PSMA SPECT/CT was 0.809

which was significantly higher compared with the two alone (

0.05).

Conclusion:

The combination of mpMRI and

99m

Tc-PSMA SPECT/CT can significantly improve the diagnostic efficiency for significant residual prostate cancer after neoadjuvant ADT.

关键词

Keywords

references

SIEGEL R L , MILLER K D , FUCHS H E , et al . Cancer statistics, 2021 [J ] . CA Cancer J Clin , 2021 , 71 ( 1 ): 7 - 33 .

HEDGIRE S , KILCOYNE A , TONYUSHKIN A , et al . Effect of androgen deprivation and radiation therapy on MRI fiber tractography in prostate cancer: can we assess treatment response on imaging? [J ] . Br J Radiol , 2019 , 92 ( 1093 ): 20170170 .

COAKLEY F V , TEH H S , QAYYUM A , et al . Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience [J ] . Radiology , 2004 , 233 ( 2 ): 441 - 448 .

HOFMAN M S , LAWRENTSCHUK N , FRANCIS R J , et al . Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study [J ] . Lancet , 2020 , 395 ( 10231 ): 1208 - 1216 .

FENDLER W P , FERDINANDUS J , CZERNIN J , et al . Impact of 68 Ga-PSMA-11 PET on the management of recurrent prostate cancer in a prospective single-arm clinical trial [J ] . J Nucl Med , 2020 , 61 ( 12 ): 1793 - 1799 .

AFSHAR-OROMIEH A , HABERKORN U , SCHLEMMER H P , et al . Comparison of PET/CT and PET/MRI hybrid systems using a 68 Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience [J ] . Eur J Nucl Med Mol Imaging , 2014 , 41 ( 5 ): 887 - 897 .

EIBER M , MAURER T , SOUVATZOGLOU M , et al . Evaluation of hybrid 68 Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy [J ] . J Nucl Med , 2015 , 56 ( 5 ): 668 - 674 .

MORIGI J J , STRICKER P D , VAN LEEUWEN P J , et al . Prospective comparison of 18 F-fluoromethylcholine versus 68 Ga-PSMA PET/CT in prostate cancer patients who have rising PSA after curative treatment and are being considered for targeted therapy [J ] . J Nucl Med , 2015 , 56 ( 8 ): 1185 - 1190 .

LAWAL I O , ANKRAH A O , MOKGORO N P , et al . Diagnostic sensitivity of Tc- 99m hynic PSMA SPECT/CT in prostate carcinoma: a comparative analysis with Ga-68 PSMA PET/CT [J ] . Prostate , 2017 , 77 ( 11 ): 1205 - 1212 .

ONAL C , GULER O C , TORUN N , et al . The effect of androgen deprivation therapy on 68 Ga-PSMA tracer uptake in non-metastatic prostate cancer patients [J ] . Eur J Nucl Med Mol Imaging , 2020 , 47 ( 3 ): 632 - 641 .

PANEBIANCO V , VILLEIRS G , WEINREB J C , et al . Prostate magnetic resonance imaging for local recurrence reporting (PI-RR): international consensus-based guidelines on multiparametric magnetic resonance imaging for prostate cancer recurrence after radiation therapy and radical prostatectomy [J ] . Eur Urol Oncol , 2021 , 4 ( 6 ): 868 - 876 .

胡四龙 , 许晓平 , 朱耀 , 等 . 99m Tc标记PSMA小分子抑制剂靶向前列腺癌分子影像初步临床研究 [J ] . 中国癌症杂志 , 2016 , 26 ( 7 ): 608 - 615 .

HU S L , XU X P , ZHU Y , et al . Preliminary clinical study of 99m Tc-labelled small molecules against PSMA for prostate cancer imaging [J ] . China Oncol , 2016 , 26 ( 7 ): 608 - 615 .

许晓平 , 张建平 , 何思敏 , 等 . 前列腺特异性膜抗原小分子抑制剂显像研究 [J ] . 肿瘤影像学 , 2015 , 24 ( 3 ): 173 - 178 .

XU X P , ZHANG J P , HE S M , et al . The imaging study of a small-molecular inhibitor targeting prostate specific membrane antigen [J ] . Oncoradiology , 2015 , 24 ( 3 ): 173 - 178 .

MCKAY R R , MONTGOMERY B , XIE W L , et al . Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade [J ] . Prostate Cancer Prostatic Dis , 2018 , 21 ( 3 ): 364 - 372 .

PETRAKI C D , SFIKAS C P . Histopathological changes induced by therapies in the benign prostate and prostate adenocarcinoma [J ] . Histol Histopathol , 2007 , 22 ( 1 ): 107 - 118 .

STABILE A , GIGANTI F , ROSENKRANTZ A B , et al . Multiparametric MRI for prostate cancer diagnosis: current status and future directions [J ] . Nat Rev Urol , 2020 , 17 ( 1 ): 41 - 61 .

KATELARIS N C , BOLTON D M , WEERAKOON M , et al . Current role of multiparametric magnetic resonance imaging in the management of prostate cancer [J ] . Korean J Urol , 2015 , 56 ( 5 ): 337 - 345 .

PADHANI A R , MACVICAR A D , GAPINSKI C J , et al . Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with MR imaging [J ] . Radiology , 2001 , 218 ( 2 ): 365 - 374 .

MURPHY W M , SOLOWAY M S , BARROWS G H . Pathologic changes associated with androgen deprivation therapy for prostate cancer [J ] . Cancer , 1991 , 68 ( 4 ): 821 - 828 .

JOSEPH I B , NELSON J B , DENMEADE S R , et al . Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue [J ] . Clin Cancer Res , 1997 , 3 ( 12 Pt 1 ): 2507 - 2511 .

BARRETT T , GILL A B , KATAOKA M Y , et al . DCE and DW MRI in monitoring response to androgen deprivation therapy in patients with prostate cancer: a feasibility study [J ] . Magn Reson Med , 2012 , 67 ( 3 ): 778 - 785 .

RØE K , SEIERSTAD T , KRISTIAN A , et al . Longitudinal magnetic resonance imaging-based assessment of vascular changes and radiation response in androgen-sensitive prostate carcinoma xenografts under androgen-exposed and androgen-deprived conditions [J ] . Neoplasia , 2010 , 12 ( 10 ): 818 - 825 .

RØE K , KAKAR M , SEIERSTAD T , et al . Early prediction of response to radiotherapy and androgen-deprivation therapy in prostate cancer by repeated functional MRI: a preclinical study [J ] . Radiat Oncol , 2011 , 6 : 65 .

CHRISTIE D R , SHARPLEY C F , MITINA N , et al . Is prospective MRI mapping of the changes in the volume of the prostate gland in prostate cancer patients undergoing 6 months of neo-adjuvant androgen deprivation therapy a step towards a trial to determine those who may benefit from treatment intensification or extended duration? [J ] . J Med Imaging Radiat Oncol , 2020 , 64 ( 2 ): 287 - 292 .

胡四龙 , 许晓平 , 朱耀 , 等 . 99m Tc-PSMA SPECT/CT探测前列腺癌病灶的临床应用价值 [J ] . 肿瘤影像学 , 2016 , 25 ( 3 ): 272 - 278 .

HU S L , XU X P , ZHU Y , et al . Clinical value of 99m Tc-PSMA SPECT/CT in detection of prostate cancer [J ] . Oncoradiology , 2016 , 25 ( 3 ): 272 - 278 .

REINFELDER J , KUWERT T , BECK M , et al . First experience with SPECT/CT using a 99m Tc-labeled inhibitor for prostate-specific membrane antigen in patients with biochemical recurrence of prostate cancer [J ] . Clin Nucl Med , 2017 , 42 ( 1 ): 26 - 33 .

GARCÍA-PÉREZ F O , DAVANZO J , LÓPEZ-BUENROSTRO S , et al . Head to head comparison performance of 99m Tc-EDDA/HYNIC-iPSMA SPECT/CT and 68 Ga-PSMA-11 PET/CT a prospec tive study in biochemical recurrence prostate cancer patients [J ] . Am J Nucl Med Mol Imaging , 2018 , 8 ( 5 ): 332 - 340 .

KWAK C , JEONG S J , PARK M S , et al . Prognostic significance of the nadir prostate-specific antigen level after hormone therapy for prostate cancer [J ] . J Urol , 2002 , 168 ( 3 ): 995 - 1000 .

EVANS M J , SMITH-JONES P M , WONGVIPAT J , et al . Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen [J ] . Proc Natl Acad Sci USA , 2011 , 108 ( 23 ): 9578 - 9582 .

VAZ S , HADASCHIK B , GABRIEL M , et al . Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients [J ] . Eur J Nucl Med Mol Imaging , 2020 , 47 ( 1 ): 9 - 15 .

浏览量

1639

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

¹⁸F-PSMA-1007 PET/CT在初诊前列腺癌精准评估中的价值及对临床治疗决策的影响

MYC通过靶向CD47促进前列腺癌增殖和转移的机制研究

《2025版美国甲状腺学会成人甲状腺结节管理指南》及《2025版美国甲状腺学会成人分化型甲状腺癌管理指南》解读：甲状腺结节及分化型甲状腺癌超声、CT、MRI以及消融部分的进展

MRI预测乳腺癌淋巴结状态的研究进展及展望

Pten^fl/fl;Trp53^fl/fl;Pbsn-iCre⁺基因编辑小鼠自发形成前列腺癌与乳腺癌的模型构建研究

mpMRI联合 99mTc-PSMA SPECT/CT检测前列腺癌新辅助雄激素剥夺治疗后显著残留病灶的价值研究

The value of mpMRI combined with 99mTc-PSMA SPECT/CT in the detection of significant residual prostate cancer after neoadjuvant androgen deprivation therapy

DOI：10.19401/j.cnki.1007-3639.2022.02.005

摘要

Abstract

关键词

Keywords

references

mpMRI联合 ^99mTc-PSMA SPECT/CT检测前列腺癌新辅助雄激素剥夺治疗后显著残留病灶的价值研究

The value of mpMRI combined with ^99mTc-PSMA SPECT/CT in the detection of significant residual prostate cancer after neoadjuvant androgen deprivation therapy